Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017096304) SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096304 International Application No.: PCT/US2016/064825
Publication Date: 08.06.2017 International Filing Date: 02.12.2016
IPC:
A61K 38/00 (2006.01) ,A61K 39/00 (2006.01) ,A61P 35/00 (2006.01) ,C07K 11/00 (2006.01) ,C07K 14/435 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
11
Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
Applicants:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 210 West 7th St. Austin, TX 78701, US
Inventors:
LIZEE, Gregory; US
YEE, Cassian; US
HWU, Patrick; US
ROSZIK, Janos; US
Agent:
FINDLAY, Geoffrey, S.; US
Priority Data:
62/263,18904.12.2015US
62/263,83507.12.2015US
Title (EN) SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
(FR) PEPTIDES SLC45A2 POUR L'IMMUNOTHÉRAPIE
Abstract:
(EN) Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
(FR) L'invention concerne des peptides SLC45A2 qui se lient au CMH I (HLA-A2) sur des cellules de mélanome ou d'autres cellules présentatrices d'antigène, et qui sont reconnus par des récepteurs des lymphocytes T sur des lymphocytes T. Les peptides SLC45A2 peuvent être utilisés en thérapeutique pour traiter un cancer, par exemple un mélanome cutané, un mélanome uvéal, un mélanome muqueux ou un mélanome métastatique. L'invention concerne également des procédés de multiplication d'une population de lymphocytes T qui ciblent les peptides SLC45A2.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2016363006CA3007301SG11201804648RIL259793EP3383418CN108601811
KR1020180118105US20190169262